Literature DB >> 29475929

Effect of Androgen-deprivation Therapy on Bone Mineral Density in Japanese Patients with Prostate Cancer.

Yoshiyuki Miyazawa1, Yoshitaka Sekine2, Takahiro Syuto2, Masashi Nomura2, Hidekazu Koike2, Hiroshi Matsui2, Yasuhiro Shibata2, Kazuto Ito2, Kazuhiro Suzuki2.   

Abstract

BACKGROUND/AIM: To evaluate bone mineral density (BMD) in Japanese patients with prostate cancer (PCa) after administering androgen deprivation therapy (ADT) for 2 years. PATIENTS AND METHODS: A total of 84 Japanese patients with PCa were enrolled in this study during the period 2008-2011. BMD was measured by dual energy X-ray absorptiometry, every 6 months. The fracture risk assessment tool (FRAX) score was calculated before starting ADT. We evaluated the change in BMD over a 2-year period and the relationship between this change, the FRAX score, and the estimated glomerular filtration rate (eGFR).
RESULTS: Compared to baseline, BMD decreased by 2.50% at 6 months after ADT, by 4.28% after 12 months, by 5.34% after 18 months, and by 6.16% after 2 years (all p<0.05). Multivariate analysis revealed that the eGFR, according to a threshold rate of 73.5 ml/min, was a significant factor in BMD.
CONCLUSION: Lumbar BMD in Japanese patients with PCa decreased by 4.28% at 1 year after ADT and by 6.16% after 2 years. We found a correlation between the decrease in BMD and the eGFR before initiating ADT, suggesting a small BMD reduction in patients with PCa who have good renal function. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Prostate cancer; androgen-deprivation therapy; bone mineral density; chronic kidney disease

Mesh:

Substances:

Year:  2018        PMID: 29475929      PMCID: PMC5905214          DOI: 10.21873/invivo.11254

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  12 in total

Review 1.  FRAX and its applications to clinical practice.

Authors:  John A Kanis; Anders Oden; Helena Johansson; Fredrik Borgström; Oskar Ström; Eugene McCloskey
Journal:  Bone       Date:  2009-02-03       Impact factor: 4.398

2.  BMD, clinical risk factors and their combination for hip fracture prevention.

Authors:  H Johansson; J A Kanis; A Oden; O Johnell; E McCloskey
Journal:  Osteoporos Int       Date:  2009-03-17       Impact factor: 4.507

3.  Bone loss in premenopausal, perimenopausal and postmenopausal women: results of a prospective observational study over 9 years.

Authors:  V Seifert-Klauss; S Fillenberg; H Schneider; P Luppa; D Mueller; M Kiechle
Journal:  Climacteric       Date:  2012-03-23       Impact factor: 3.005

4.  Importance of bone mineral density measurements in evaluating fragility bone fracture risk in Asian Indian men.

Authors:  K Kuruvilla; A M Kenny; L G Raisz; J E Kerstetter; R S Feinn; T V Rajan
Journal:  Osteoporos Int       Date:  2010-05-06       Impact factor: 4.507

5.  Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma.

Authors:  J F Maillefert; J Sibilia; F Michel; C Saussine; R M Javier; C Tavernier
Journal:  J Urol       Date:  1999-04       Impact factor: 7.450

6.  Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.

Authors:  Alfredo Berruti; Luigi Dogliotti; Carlo Terrone; Stefania Cerutti; Giancarlo Isaia; Roberto Tarabuzzi; Giuseppe Reimondo; Mauro Mari; Paola Ardissone; Stefano De Luca; Giuseppe Fasolis; Dario Fontana; Salvatore Rocca Rossetti; Alberto Angeli
Journal:  J Urol       Date:  2002-06       Impact factor: 7.450

7.  Progressive osteoporosis during androgen deprivation therapy for prostate cancer.

Authors:  H W Daniell; S R Dunn; D W Ferguson; G Lomas; Z Niazi; P T Stratte
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

8.  Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer.

Authors:  Yoshiyuki Miyaji; Takashi Saika; Yasuo Yamamoto; Nobuyuki Kusaka; Ryoji Arata; Shin Ebara; Yasutomo Nasu; Tomoyasu Tsushima; Hiromi Kumon
Journal:  Urology       Date:  2004-07       Impact factor: 2.649

9.  Changes in bone mineral density differ between gonadotrophin-releasing hormone analogue- and surgically castrated men with prostate cancer--a prospective, controlled, parallel-group study.

Authors:  Ingrid Bergström; Hans Gustafsson; Kerstin Sjöberg; Stefan Arver
Journal:  Scand J Urol Nephrol       Date:  2004

Review 10.  Prostate cancer in Asian men.

Authors:  Kazuto Ito
Journal:  Nat Rev Urol       Date:  2014-03-04       Impact factor: 14.432

View more
  2 in total

Review 1.  Multidisciplinary Approach for Bone Metastasis: A Review.

Authors:  Takahiro Kimura
Journal:  Cancers (Basel)       Date:  2018-05-24       Impact factor: 6.639

Review 2.  Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers.

Authors:  Erin Choi; John Buie; Jaime Camacho; Pranav Sharma; Werner T W de Riese
Journal:  Res Rep Urol       Date:  2022-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.